Sertagen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sertagen

Property Description
Active ingredient Sertraline
Form Oral tablets (typically film-coated)
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common purpose Systemic mood stabilization
Origin Synthetic organic compound

What Type of Medicine is Sertagen? (Identity and Classification)

Sertagen is a prescription-only psychotropic agent containing the active compound Sertraline, and it is primarily classified as an antidepressant. The drug is a synthetic organic compound that belongs to the modern class of medications known as Selective Serotonin Reuptake Inhibitors (SSRIs). This classification defines its specific action on the brain's neurochemistry. This classification reflects its use in addressing underlying chemical imbalances.

Sertraline's classification as an SSRI is central to its therapeutic role. As an SSRI, this medication works by helping to restore the balance of certain natural substances in the brain. These medications are an established first-line pharmacological method for addressing chemical imbalances related to emotional health.


Composition, Origin, and Dosage Form (The Physical Entity)

The core composition of Sertagen is the active ingredient, Sertraline, typically formulated as Sertraline hydrochloride. This confirms Sertagen as a single-ingredient product, where the therapeutic effect is derived exclusively from the Sertraline compound. It is supplied for oral administration, most commonly in the form of oral tablets (often film-coated tablets).

The oral tablet form ensures the consistent and standardized unit-dose delivery of the Sertraline hydrochloride to the digestive system for systemic absorption. The compound is a complex synthetic drug, reflecting its targeted chemical structure, which requires continuous systemic presence in the body to achieve its general purpose.


General Purpose and Action of an SSRI

The general purpose of Sertagen is to help stabilize mood and alleviate the general symptoms of anxiety by modulating key brain chemicals. Sertraline achieves this by its core mechanism: acting as a potent inhibitor of the reuptake of the neurotransmitter serotonin (5-HT).

By blocking the rapid clearance of serotonin from the synaptic space, Sertagen effectively increases the availability of serotonin to signal between nerve cells. This enhanced serotonergic neurotransmission is the general mechanism that supports the drug’s overall therapeutic goal of emotional regulation, such as helping an individual manage persistent feelings of worry or sadness. Sertraline is categorized as an SSRI within the group of psychoanaleptics.

Regulatory References

  1. MedlinePlus Sertraline Drug Information

What side effects are possible with Sertagen?

Possible Side Effects and Safety Information

Sertagen (Sertraline) is associated with officially documented adverse reactions that are categorized by both frequency and the body system affected, consistent with regulatory classifications from agencies like the EMA and FDA.

Frequency-Classified Adverse Reactions

The following are classified based on regulatory frequency frameworks:

  • Very Common (Affecting 1 in 10 or more people): Nausea, insomnia, dizziness, headache, dry mouth, somnolence (drowsiness), fatigue, ejaculation failure, and increased sweating (hyperhidrosis).
  • Common (Affecting up to 1 in 10 people): Decreased appetite, anxiety, palpitations, dyspepsia, tremor, visual impairment, and erectile dysfunction.

Serious Adverse Reactions and Safety Constraints

Official labeling documents serious adverse reactions that are potentially life-threatening or clinically significant. These include the documented potential for Serotonin Syndrome and Neuroleptic Malignant Syndrome (NMS)-like reactions (frequency not known). There is a specific regulatory consideration for an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) during short-term use. Other documented serious reactions include abnormal bleeding/haemorrhage, hyponatremia (low sodium levels), and the potential for QTc prolongation.

Safety notes also exist for specific populations. Older adults may be at greater risk of developing hyponatremia. The drug should be avoided in patients with unstable epilepsy and requires caution in patients with hepatic impairment. Exposure-related patterns are noted, with gastrointestinal effects often being transient upon treatment initiation, while abrupt discontinuation may lead to discontinuation syndrome.

Overdose and Emergency Response

Overdose and When to Seek Help

This section is derived exclusively from authoritative government regulatory sources and outlines the officially documented clinical manifestations and required emergency procedures for a Sertraline overdose.


Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Somnolence, nausea, vomiting, tachycardia, tremor, agitation, dizziness.
Physiological systems affected (as stated in label) Central Nervous System (CNS), Cardiovascular, Gastrointestinal, Autonomic.
Exposure-related factors (if applicable) Increased risk of toxicity, including death, when co-ingested with other drugs and/or alcohol.
Emergency-response statements Seek immediate medical attention for any suspected overdose. Call emergency services if the victim has collapsed, has had a seizure, or has trouble breathing.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Overdose may be associated with severe outcomes including coma, seizures, and death; requires hospital monitoring.
Overdose-context constraints No specific antidote is known. Management is limited to symptomatic and supportive treatment.

Resulting Overdose Structure

Official overdose statements:

  • Documented manifestations often include somnolence, tremor, agitation, nausea, and vomiting.
  • Severe outcomes formally documented in regulatory labeling include seizures, coma, Serotonin Syndrome, QTc prolongation, and death, particularly in mixed overdose.
  • Immediate medical attention is mandated for any suspected overdose or for the onset of severe symptoms like collapse or profound agitation.
  • No specific antidote is known; therefore, treatment is based on symptomatic and supportive measures, including establishing an airway and continuous cardiac monitoring.
  • Hospital monitoring and observation for a minimum of 12 hours are required regulatory procedures in the management of overdose.

Connection to the overall overdose profile: The regulatory documents define the Sertraline overdose profile by specifying the documented spectrum of clinical manifestations and the potential severe outcomes that may arise, such as seizures or Serotonin Syndrome. Because no specific antidote is available, this profile mandates that immediate medical attention is required for any suspected overdose, with hospital monitoring and symptomatic support serving as the primary procedural measures. The official documentation notes that the risk of toxicity and mortality is elevated when co-ingestion with other drugs or alcohol occurs.

Therapeutic Uses of Sertagen

Main Therapeutic Uses

Sertagen, which contains the active ingredient sertraline, is a medication belonging to the group of Selective Serotonin Reuptake Inhibitors (SSRIs). It is primarily used to manage several mental health and emotional conditions by helping to restore the balance of serotonin in the brain.

Major Depressive Disorder

The primary use of Sertagen is the treatment of major depressive disorder. It is used to alleviate persistent feelings of sadness, low mood, and loss of interest in daily activities. It also helps in preventing the recurrence of depressive episodes in individuals who have responded well to initial treatment.

Anxiety and Stress-Related Disorders

Sertagen is utilized in the management of several specific anxiety-related conditions:

  • Panic Disorder: It is used to reduce the frequency and intensity of panic attacks, including the physical symptoms and the fear of future occurrences.
  • Social Anxiety Disorder: The medication helps manage the intense fear of social situations or performance-based environments where scrutiny by others is expected.
  • Post-Traumatic Stress Disorder (PTSD): It is indicated for the treatment of emotional distress following exposure to traumatic events.
  • Obsessive-Compulsive Disorder (OCD): In both adults and pediatric populations, it is used to manage repetitive thoughts and the urge to perform ritualistic behaviors.

Premenstrual Dysphoric Disorder (PMDD)

Sertagen is also used to treat the severe emotional and physical symptoms associated with PMDD, a condition characterized by significant mood swings, irritability, and tension occurring in the week before menstruation.

Benefits and Clinical Goals

Individual responses to the medication can vary, but the general goals of treatment include:

  • Stabilization of Mood: Helping to level out emotional peaks and valleys to support daily functioning.
  • Improvement in Sleep and Appetite: Addressing the physical disruptions often caused by depression and anxiety.
  • Reduction of Avoidance Behaviors: Assisting individuals with social anxiety or PTSD in engaging more comfortably with their environments.
  • Control over Compulsive Thoughts: Reducing the time spent on obsessions and compulsions in cases of OCD.

Regulatory References

  1. European Commission's Union Register

Eligibility and Restrictions for Use

Official Eligibility and Restriction Profile for Sertagen (Sertraline)

The official population eligibility for using Sertagen is strictly defined by regulatory authorities based on age, concurrent medication use, and specific pre-existing health conditions.

Absolute Non-Eligibility (Contraindications)

Sertagen is contraindicated and must not be used in the following patient groups, as stated in regulatory labels:

  • Patients with known hypersensitivity to the active substance (Sertraline) or any of the tablets’ excipients.
  • Patients taking Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI (due to the risk of Serotonin Syndrome).
  • Patients receiving concurrent therapy with Pimozide.

Age-Related Eligibility and Limitations

Age Group Eligibility Status (Regulatory Wording)
Adults (18+ years) Eligible (Standard approved population)
Children & Adolescents (6–17 years) Restricted Use (Approved only for Obsessive-Compulsive Disorder)
Children under 6 years Use Not Established (Safety and efficacy data are not available)

Conditional Use and Organ Function Restrictions

Use requires special caution or is restricted in patients with specific health conditions, as documented by official labeling:

  • Hepatic Impairment: Use is approached with caution, and Sertagen should not be used in cases of severe hepatic impairment due to increased exposure.
  • Unstable Epilepsy: Sertagen should be avoided in patients with unstable epilepsy, and patients with controlled epilepsy must be monitored.
  • Pregnancy and Lactation: Use is generally not recommended unless essential; Sertraline is known to be excreted into breast milk, and third-trimester use is associated with neonatal withdrawal symptoms.

What should I know about interactions with other medicines?

Certain combinations with Sertagen (Sertraline) are strictly contraindicated by regulatory agencies. Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Methylene Blue Injection, is prohibited due to the risk of a severe serotonergic reaction. The use of Pimozide is also disallowed, as Sertraline significantly increases its plasma concentration.

The official interaction profile highlights specific pharmacodynamic risks. Concomitant use with other serotonergic agents (e.g., Triptans, Tramadol) increases the documented risk of Serotonin Syndrome. Combining Sertagen with drugs that interfere with hemostasis (e.g., NSAIDs or Warfarin) increases the potential for Abnormal Bleeding.

Sertraline is a mild-to-moderate inhibitor of the CYP2D6 isoenzyme, a pharmacokinetic interaction that may result in elevated plasma exposure of co-administered medicines metabolized by this pathway. Patients with hepatic impairment may experience increased Sertraline exposure due to reduced clearance.

Mandatory administration timing rules govern the use of MAOIs. A minimum 14-day washout period is required when switching from an MAOI to Sertagen, and 7 days when switching from Sertagen to an MAOI. The herbal product St. John's Wort is also cautioned against due to increased serotonergic risk, and alcohol co-administration is not recommended.

Mechanism of Action

The Primary Mechanism: Selective Serotonin Reuptake Inhibition

Sertagen's mechanism begins with its primary action as a selective inhibitor of the Serotonin Transporter ( SERT) protein on nerve cells. By blocking the reabsorption (reuptake) of serotonin (5 HT) back into the presynaptic neuron , the drug rapidly and predictably increases the concentration of free serotonin within the synaptic cleft. This foundational molecular action is necessary to initiate the subsequent chain of adaptive physiological responses.


Neurotransmitter System Adaptation and Time-Dependent Effect

The therapeutic manifestation of the mechanism relies on the system's adaptation to the chronic elevation of synaptic serotonin. This involves the gradual desensitization and down-regulation of inhibitory 5HT autoreceptors, which allows the neurons to overcome their initial self-regulation. This necessary, time-dependent change enhances the signal's strength, leading to the sustained and normalized serotonergic tone in CNS circuits involved in physiological regulation.


Ancillary Interaction and Mechanistic Constraints

Sertraline also engages in a secondary interaction by binding to the Sigma-1 Receptor (sigma1), an ancillary mechanism that may modulate cellular plasticity and influence the drug's overall pharmacological action. However, the mechanism is subject to constraints, primarily the biological variability of the SERT and receptor systems, which may limit the degree of adaptive change and explains why the full mechanistic potential may be partial or absent in some individuals due to biological non-responsiveness.

Dosage and Administration Information

How to Use Sertagen: Official Administration Guidelines

Sertagen, which contains the active ingredient Sertraline, is administered exclusively via the oral route. The medicine is designed for a consistent once-daily frequency, which may be taken in the morning or the evening. This regimen ensures a sustained systemic presence of the compound.

The standard approach involves initiating treatment with a low starting dose, typically 50 mg for most adult indications, or 25 mg for specific anxiety and panic disorders. The maximum recommended daily dose for adults across most approved uses is 200 mg.


Dosing Protocol and Administration

Administration is procedural and involves a period of dose adjustment, or titration. Increases in dose, ranging from 25 mg to 50 mg, must occur at intervals of no less than one week. The oral tablets may be taken with or without food as this does not significantly impede absorption. However, the oral concentrate solution must be diluted immediately before consumption using approved liquids such as water or certain sodas.

For specific populations, information includes starting doses for children and adolescents with Obsessive-Compulsive Disorder (OCD), and caution for patients with hepatic impairment, who may require a half-dose regimen. Because Sertagen is intended for long-term use, it is recommended that a gradual dose reduction (tapering) be followed when discontinuation is necessary.

Recent Clinical Evidence

Research evidence / Overview of studies for Sertagen


Evidence for use in Major Depressive Disorder (MDD)

Sertagen was studied for use in Major Depressive Disorder (MDD) primarily through short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, typically tracking adult patients for eight to twelve weeks. Researchers were examining the severity of depressive symptoms using standardized scales. The evidence contributes to the broader evidence landscape and the understanding of short-term and intermediate symptom patterns.

For patients who were observed in these initial studies, subsequent longer-term trials were conducted to examine outcomes related to the return of depressive symptoms. However, the majority of pivotal research focused on the short-term (acute) symptom changes, meaning there is limited information for long-term outcomes and functional stability over many years. The results apply only to the populations studied, and data for certain groups remain insufficient.


Evidence for use in Anxiety-Related Conditions (OCD, PD, and PTSD)

Research has also explored the use of Sertagen in conditions characterized by fluctuating or episodic manifestations, including Obsessive-Compulsive Disorder (OCD), Panic Disorder (PD), and Post-Traumatic Stress Disorder (PTSD). For OCD, Randomized Controlled Trials (RCTs) were observed in both adults and specific pediatric and adolescent populations. Research focused on outcomes related to functional imbalance, specifically tracking changes in obsessive and compulsive behaviors using dedicated scales.

In Panic Disorder (PD) and Post-Traumatic Stress Disorder (PTSD), studies focusing on episodes where symptoms become more noticeable was evaluated in trials exploring short-term symptom changes. Outcomes for certain PTSD populations reportedly were mixed. This variability indicates that while research is ongoing, evidence quality varies across studies, and certainty remains low in some specific subgroups.


Research Gaps and Areas of Uncertainty

A key limitation is that follow-up durations were limited across most indications, leading to limited information for long-term outcomes and recurrence prevention over a long period. Furthermore, sample sizes were modest in some key subgroup analyses, and this means that subgroup findings are uncertain. Comparative evidence is lacking for many direct, head-to-head research comparisons against other treatments.

Key Studies & References Sertraline as a treatment for PTSD: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Sertagen (FAQ)

Q: How does Sertagen compare to similar prescription drugs?

A: Studies and official information indicate that Sertraline, an SSRI, is comparable in effectiveness to other medications in its class and older treatments like tricyclic antidepressants (TCAs). Research suggests it is tolerated differently than TCAs.

Q: How long does it typically take for Sertagen to start working?

A: According to official product information, Sertraline reaches a consistent level in the body after about seven days of once-daily dosing. However, the full therapeutic effect relies on the body's time-dependent adaptation to the medication and often takes several weeks or longer to fully manifest.

Q: Can Sertagen be taken with common over-the-counter pain relievers?

A: Official interaction warnings highlight that combining Sertraline with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, increases the potential for abnormal bleeding. The regulatory warnings regarding this risk do not generally apply to over-the-counter pain relievers that are not NSAIDs, such as acetaminophen.

Q: Are there any specific foods or drinks to avoid while using Sertagen?

A: Regulatory documents state that no specific food restrictions are listed; tablets may be taken with or without food. However, patients are officially cautioned against the co-administration of alcohol due to potential interaction effects.

Q: Can Sertagen be used by people over 65?

A: Yes, the medication is approved for use in adults, which includes individuals over 65. Official information notes that older patients may process the medication more slowly, potentially resulting in higher levels in the body, which is a key consideration documented in the product label.

Q: Can Sertagen affect my ability to drive or operate machinery?

A: As noted in patient safety warnings, this medication may affect coordination, reaction time, or judgment due to certain side effects. Regulatory labels contain a warning about driving or operating complex machinery until a patient understands how the medication affects their individual capacity.

Q: Does Sertagen have any known long-term side effects?

A: The medication is authorized for long-term use. Although research data focused on outcomes over many years is limited, official labeling lists documented adverse reactions that may persist or appear with extended use.

Q: Why is Sertagen typically taken at a specific time of day?

A: Sertraline is taken once daily and maintains a consistent level in the body regardless of timing. The choice between morning or evening is typically related to managing common side effects, such as taking it at night to manage daytime drowsiness or in the morning if insomnia is a factor.

Q: What kind of monitoring might be needed while using Sertagen?

A: Official regulatory documents mention certain monitoring procedures, especially for patients with other conditions. This may include checking for signs of abnormal bleeding and monitoring sodium levels in the blood due to the documented risk of hyponatremia (low sodium). ECG monitoring is also mentioned in certain high-risk situations.

Q: What should I do if I miss taking Sertagen?

A: The official product information outlines a protocol for a missed dose, which involves taking the missed dose as soon as it is remembered unless it is near the time for the next scheduled dose. The protocol includes a warning that a double dose should not be taken to make up for a forgotten one.

Q: Is Sertagen known to cause weight changes?

A: Official documents report that weight gain is a possible adverse reaction. Weight and appetite changes can be complicated, sometimes resulting from a general improvement in a person's condition or mood.

Q: How quickly does the effect of one dose of Sertagen wear off?

A: The active ingredient, Sertraline, has an average elimination half-life of about 26 hours. Furthermore, its primary metabolite remains active in the body for an even longer duration, which supports the drug’s sustained systemic effect with once-daily dosing.

Q: What happens if Sertagen is taken longer than recommended?

A: Official documents confirm the medication is approved for long-term treatment. Use for periods beyond a specific recommendation is subject to the patient's overall care plan and ongoing assessment.

Q: Is Sertagen classified as a controlled substance?

A: No, Sertraline is not classified as a controlled substance by government regulators. This classification reflects that the medication has low potential for abuse or misuse.

Q: Why do some people say they feel restless when starting Sertagen?

A: Restlessness is a subjective symptom that has been reported. It is sometimes connected to officially documented central nervous system effects such as tremor or agitation that can be experienced, particularly when starting the medication.

Q: Is Sertagen associated with any risk of dependence?

A: The medication is not associated with a risk of addiction or abuse. However, like many medications used long-term, prolonged use can lead to physical dependence, which is why official product information includes instructions for a gradual dose reduction when stopping.

Q: Are there generic versions of Sertagen available?

A: Yes, the active ingredient, Sertraline, is available in both a brand name and a generic form.

Q: What specific warnings are listed about Sertagen and kidney problems?

A: Official studies show that renal impairment (kidney problems) does not significantly affect the way Sertraline is processed by the body. Research findings indicate that dose adjustment is not required based solely on kidney function.

Q: Can Sertagen affect blood pressure?

A: Clinical studies have generally indicated no adverse effects on blood pressure or other core cardiovascular measurements.

Q: Can Sertagen be taken with daily vitamins?

A: Regulatory information does not list any specific adverse interactions between Sertraline and typical daily vitamin supplements.

Q: Is there a patient support program related to Sertagen?

A: Yes, patient assistance programs are available through the manufacturer of the brand name product. Additionally, non-profit resources offer similar programs to help eligible patients with medication cost and access.

Q: Are there financial assistance options for Sertagen?

A: Financial assistance may be available through the manufacturer’s patient assistance program for eligible patients who meet specific criteria. Resources provided by non-profit organizations may also be explored.

How should Sertagen be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Sertagen — Official Regulatory Information

Storage & disposal scope

Labeled storage temperature requirements: Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C. Light/moisture protection requirements: Keep the medication in the original container and ensure it is tightly closed to protect it from moisture and excess heat. The oral solution must be protected from light. Stability after opening/reconstitution (if applicable): The oral concentrate must be diluted immediately before administration and should not be stored after dilution. Disposal instructions (as documented in government sources): Unused or expired Sertagen should be disposed of via a drug take-back program. If a program is unavailable, the product must be mixed with an undesirable substance (e.g., coffee grounds, cat litter), sealed in a container, and discarded in the household trash. Child-protection storage requirements (if stated): Keep this medication out of the sight and reach of children.

Storage/disposal classifications (high-level)

Storage condition type (e.g., room temperature / refrigerated / protect from light): Controlled Room Temperature, Protect from Moisture and Light. Regulatory basis (EMA / FDA / etc.): FDA DailyMed, NIH MedlinePlus, and official disposal guidance.

Connection to the overall storage/disposal profile (2–4 sentences): Regulatory documents strictly mandate that Sertagen must be stored at Controlled Room Temperature to ensure product stability. This temperature control is paired with the requirement to keep the product in its original, tightly closed container, protecting it from both light and moisture. Disposal procedures require that unused product is returned via a take-back program or securely disposed of in household trash to prevent environmental release and accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sertagen found in:

A-Z Index: